McKesson Total Revenue decreased by 9.3% to $96.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $90.82B to $96.30B. Over 4 years (FY 2022 to FY 2026), Total Revenue shows an upward trend with a 11.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.67B | $66.58B | $68.61B | $66.10B | $67.15B | $70.16B | $70.49B | $68.91B | $74.48B | $77.22B | $80.90B | $76.36B | $79.28B | $93.65B | $95.29B | $90.82B | $97.83B | $103.15B | $106.16B | $96.30B |
| QoQ Change | — | +6.2% | +3.1% | -3.7% | +1.6% | +4.5% | +0.5% | -2.2% | +8.1% | +3.7% | +4.8% | -5.6% | +3.8% | +18.1% | +1.8% | -4.7% | +7.7% | +5.4% | +2.9% | -9.3% |
| YoY Change | — | — | — | — | +7.1% | +5.4% | +2.7% | +4.2% | +10.9% | +10.1% | +14.8% | +10.8% | +6.4% | +21.3% | +17.8% | +18.9% | +23.4% | +10.1% | +11.4% | +6.0% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | $2.64B | $2.95B | $2.95B | $2.85B | $2.70B | $2.95B | $2.99B | $2.87B |
| Prescription Technology Solutions | $1.24B | $1.27B | $1.37B | — | $1.43B | $1.38B | $1.50B | $1.50B |
| Corporate | — | $3.00M | $4.00M | — | — | — | — | — |
| International | $3.69B | $3.71B | $3.86B | $3.46B | $3.74B | — | — | — |
| North American Pharmaceutical | — | — | — | — | — | $86.48B | $88.32B | — |
| Oncology & Multispecialty | — | — | — | — | — | $12.04B | $13.01B | — |
| U.S. Pharmaceutical | $71.72B | $85.73B | $87.11B | $83.17B | $89.95B | — | — | — |
| Total | $79.28B | $93.65B | $95.29B | $90.82B | $97.83B | $103.15B | $106.16B | $96.30B |
Corporate, International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.